We Can Medicines Co., Ltd. (TPEX:6929)
Taiwan · Delayed Price · Currency is TWD 23.35
+0.95 (4.24%)
Aug 20, 2026, 11:13 AM CST
We Can Medicines Revenue
We Can Medicines had revenue of 802.61M TWD in the quarter ending June 30, 2026, a decrease of -1.74%. This brings the company's revenue in the last twelve months to 3.21B, down -1.09% year-over-year. In the year 2025, We Can Medicines had annual revenue of 3.22B, down -1.45%.
Revenue (ttm)
3.21B
Revenue Growth
-1.09%
P/S Ratio
0.33
Revenue / Employee
3.14M
Employees
1,020
Market Cap
1.05B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.22B | -47.40M | -1.45% |
| Dec 31, 2024 | 3.27B | 146.31M | 4.69% |
| Dec 31, 2023 | 3.12B | -179.84M | -5.45% |
| Dec 31, 2022 | 3.30B | 508.66M | 18.21% |
| Dec 31, 2021 | 2.79B | 127.32M | 4.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fwusow Industry | 14.38B |
| Wonder Pets Enterprises | 3.47B |
| Tai Roun Products | 3.28B |
| Ten Ren Tea | 2.20B |
| Eagle Cold Storage Enterprise | 2.11B |
| Lian Fa International Dining Business | 1.27B |
| SunWay Biotech Co., LTD. | 993.30M |
| Hantech Bio-Technology | 864.73M |